GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (FRA:0PT) » Definitions » Debt-to-Revenue

Prothena (FRA:0PT) Debt-to-Revenue : 1.28 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Prothena Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Prothena's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €2.5 Mil. Prothena's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €7.9 Mil. Prothena's annualized Revenue for the quarter that ended in Dec. 2024 was €8.1 Mil. Prothena's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 1.28.


Prothena Debt-to-Revenue Historical Data

The historical data trend for Prothena's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Debt-to-Revenue Chart

Prothena Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.92 0.06 0.12 0.13 0.08

Prothena Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.36 62.48 0.02 2.96 1.28

Competitive Comparison of Prothena's Debt-to-Revenue

For the Biotechnology subindustry, Prothena's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Prothena's Debt-to-Revenue falls into.


;
;

Prothena Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Prothena's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.493 + 7.863) / 129.075
=0.08

Prothena's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.493 + 7.863) / 8.108
=1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Prothena Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Prothena's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Prothena Headlines

No Headlines